SEC Filing Analysis: ANGIODYNAMICS INC (ANGO)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Executive Vice President and Chief Financial Officer, Stephen A. Trowbridge, executed a small open-market purchase of company stock, valued at approximately $9,932.
• Market Impact: The transaction is expected to have a neutral market impact due to its small size. It represents a minor increase in the executive's already significant holdings and is unlikely to influence broader investor sentiment.

Company Information

Field	Value
Company	ANGIODYNAMICS INC
Ticker Symbol	ANGO
CIK	0001275187
Industry	Surgical & Medical Instruments & Apparatus [3841]

Insider Information

Field	Value
Name	Trowbridge Stephen A
CIK	0001624250
Title/Position	EVP and CFO
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-10-13
Transaction Code	P (Open market purchase)
Security Type	Common Stock
Shares Involved	890
Price Per Share	$11.16
Total Value	$9,932.40
Shares Owned After	256,629
Ownership Type	Direct

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The total value of the transaction is less than $10,000. While insider buying is generally a positive signal, the small scale of this purchase suggests it is not a high-conviction trade intended to signal a major upcoming catalyst. It is more likely a routine accumulation or portfolio adjustment.

Volume & Sentiment

• Expected Volume Impact: Negligible. The transaction size is too small to have a noticeable effect on trading volume.
• Sentiment Indicator: Neutral to slightly Bullish. The action of a CFO buying shares is a positive, but the low value tempers the bullish sentiment.

Investment Insights

Positive Market Indicators

• An executive-level insider is increasing their direct ownership, which aligns their interests more closely with shareholders.
• The purchase was made on the open market, indicating the use of personal funds.

Risk Factors

• The transaction size is nominal and does not provide a strong signal about the company's future prospects.
• Over-interpreting this small purchase as a major bullish signal could be a significant risk.

Key Takeaways

1. Routine Purchase: The CFO's purchase of 890 shares is a minor addition to their existing holding of over 256,000 shares.
2. Low Signal Strength: The trade's value is too low to be considered a significant insider signal.
3. Alignment Confirmation: The action reinforces the executive's vested interest in the company's performance, but does not necessarily predict short-term stock movement.

Contextual Analysis

Timing Significance

• The transaction occurred on a regular trading day without any immediate proximity to major corporate announcements noted in the filing, suggesting it was not driven by a specific near-term event.

Transaction Context

• The filing does not indicate that this transaction was made under a Rule 10b5-1 trading plan. This was a discretionary open-market purchase.

Company Context

• AngioDynamics operates in the surgical and medical instruments sector. This trade should be viewed in the context of the company's recent performance, earnings reports, and developments within the medical device industry.

Risk Assessment

Risk Level: Low

Risk Factors

• Misinterpretation: The primary risk is assigning too much importance to a very small insider transaction.
• Lack of Information: The filing provides no additional context that would elevate the significance of this trade.
• Market Noise: This transaction is likely to be lost in the daily noise of market activity.

Market Considerations

• Broader market trends and sector-specific news will have a much greater impact on ANGO's stock price than this individual trade.
• Investors should focus on the company's fundamental financial health and strategic initiatives.
• This filing is a minor data point and should not form the basis of an investment decision.

---

IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.

Analysis generated on 2025-10-14 | Data source: SEC EDGAR